44 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27216999	30	Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.	The Fifth Affiliated Hospital of Guangzhou Medical University
25468037	76	Synthesis and evaluation of N-acyl-substituted 1,2-benzisothiazol-3-one derivatives as caspase-3 inhibitors.	TBA
25358116	84	Synthesis of 7-halogenated isatin sulfonamides: nonradioactive counterparts of caspase-3/-7 inhibitor-based potential radiopharmaceuticals for molecular imaging of apoptosis.	Westf£Lische Wilhelms-Universit£T M£Nster
24656804	44	1,2-benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors.	Tianjin University of Science and Technology
23685941	53	Influence of 4- or 5-substituents on the pyrrolidine ring of 5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin derivatives on their inhibitory activities towards caspases-3 and -7.	Westf£Lische Wilhelms-Universit£T M£Nster
23656488	18	Synthesis, 18F-radiolabeling, and in vivo biodistribution studies of N-fluorohydroxybutyl isatin sulfonamides using positron emission tomography.	Westf£Lische Wilhelms-Universit£T M£Nster
23411396	60	Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: nonradioactive counterparts of putative PET-compatible apoptosis imaging agents.	Westf£Lische Wilhelms-Universit£T M£Nster
24900651	50	Irreversible inhibitors of cysteine proteases.	Dart Neuroscience
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
14980679	30	Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid.	Maxim Pharmaceuticals
21441025	147	Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay.	Washington University
20541849	21	Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study.	University of Lisbon
19445513	82	Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis.	Westfalische Wilhelms-Universitat
19299147	60	Fluorinated isatin derivatives. Part 1: synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatins as potent caspase-3 and -7 inhibitors.	WestfäLische Wilhelms-UniversitäT
19049429	70	Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide.	Imperial College
18387304	4	Structure-based discovery of a novel non-peptidic small molecular inhibitor of caspase-3.	Tokyo University of Science
17889532	23	Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P(2) amino acid by 2-aminoaryl acids and other non-natural amino acids.	Epicept
17585855	65	Isatin sulfonamide analogs containing a Michael addition acceptor: a new class of caspase 3/7 inhibitors.	Washington University
17251019	30	Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones.	Merck Frosst Centre For Therapeutic Research
17181147	10	Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo.	University of Edinburgh
17154501	121	5-pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis.	University Hospital of The WestfäLische Wilhelms-UniversitäT
16891117	5	Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis.	Washington University
15713391	19	Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P2 alpha-amino acid by a alpha-hydroxy acid.	Maxim Pharmaceuticals
15686936	210	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.	Merck Frosst Centre For Therapeutic Research
15454214	26	Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group.	Maxim Pharmaceuticals
12270186	99	Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.	Idun Pharmaceuticals
12270185	257	Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization.	Idun Pharmaceuticals
27563406	128	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.	Roche Pharma Research and Early Development
10978183	40	Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery.	Basf Bioresearch
28615111	24	Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives.	Universit£
29648825	47	Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.	Nestl�
12757844	9	In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand.	Merck Research Laboratories
9108306	17	Molecular cloning and characterization of a new receptor for galanin.	Merck Research Laboratories
18812261	8	The molecular interactions of buspirone analogues with the serotonin transporter.	National Medicines Institute
18307303	75	Discovery of selective aminothiazole aurora kinase inhibitors.	Novartis
18800762	61	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.	National Taiwan University
18308563	39	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.	Irbm/Merck Research Laboratories
17685602	33	Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.	Targegen
18754654	19	The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .	Piramed Pharma
14698155	68	Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.	Bristol-Myers Squibb